ERBB2 and lung carcinoma: In this regard, a recent case report shows that a patient with EGFR-mutated lung cancer who developed resistance to osimertinib and expressed exon 20 insertion mutation in HER2 gained approximately 8 months of benefit from the combination of the third-generation EGFR TKI and trastuzumab deruxtecan [160].